CVS Caremark Announces Agreement with FTC To Further Advance Industry-Leading Approaches to Transparency and Affordability
Rhea-AI Summary
CVS (NYSE: CVS), through CVS Caremark, announced a global settlement with the Federal Trade Commission that resolves all outstanding FTC litigation and investigations involving its pharmacy benefit management and affiliated pharmacy businesses, including rebate, pharmacy network contracting, and vertical integration issues.
According to CVS Caremark, the agreement removes ongoing legal overhang and formalizes a series of changes aimed at affordability and transparency, such as aligning member cost sharing with net drug costs, moving away from rebate guarantees and spread pricing, and expanding detailed reporting on drug prices, rebates, and member payments.
CVS Caremark reported negotiating nearly $80 billion in client and member prescription savings last year, delivering nearly $900 million in point-of-sale rebates to 25 million Americans, and expects clients to drive about $450 million in annual savings over each of the next 10 years through expanded point-of-sale rebate adoption and related innovations.
Positive
- Global FTC settlement resolves all outstanding litigation and investigations
- CVS Caremark negotiated nearly $80 billion in prescription drug savings last year
- Point-of-sale rebates delivered nearly $900 million to 25 million Americans last year
- Expected client savings of about $450 million per year for next 10 years
- Insulin affordability program capping member costs at $25 per month
- Transition to acquisition-based reimbursement may improve alignment with independent pharmacy costs
Negative
- Settlement requires multiple structural changes to pricing and transparency practices under FTC-established timelines
News Explained
The settlement makes CVS Caremark’s listed commercial-client affordability and transparency measures committed implementation items, but dates and financial effects remain unspecified.
The
The listed changes include tying certain member cost sharing more closely to post-rebate drug costs, moving away from rebate guarantees and spread pricing, expanding reporting on rebates and compensation, and shifting independent-pharmacy reimbursement toward acquisition costs.
Some provisions remain conditional: TrumpRx purchases will count toward deductibles and out-of-pocket maximums only where permitted by law and subject to settlement conditions, while a new insulin offering is described at
The concrete follow-up is implementation against timelines established with the FTC; the release does not provide dates for those timelines or quantify the financial effect of the operating changes.
News Market Reaction – CVS
In the Jul 14 session, CVS gained 0.26%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 10 | Dividend declaration | Positive | +1.3% | Board approved a quarterly cash dividend of $0.665 per share. |
| Jul 06 | Earnings call scheduling | Neutral | -2.5% | Announced date and time for second quarter 2026 earnings call. |
| Jun 25 | Community investment | Positive | +2.7% | Committed $1 million in Hometown Fund grants to 20 Hartford nonprofits. |
| Jun 25 | Community investment | Positive | +2.7% | Invested $1 million via Hometown Fund in 20 Rhode Island nonprofits. |
| Jun 22 | GLP‑1 program expansion | Positive | +3.6% | Expanded GLP‑1 support and lower-cost access, including defined monthly copay options. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CVS headlines have more often coincided with positive share-price reactions, particularly around strategic and community-focused initiatives.
Key Terms
point-of-sale rebates financial
rebate guarantees financial
spread pricing financial
acquisition-based reimbursement financial
biosimilars medical
deductibles financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The agreement eliminates the need for ongoing litigation and investigations and allows CVS Caremark to remain focused on delivering more value for American consumers and employers, lowering prescription drug costs, increasing transparency, and helping customers deliver affordable health care to the people they serve.
"CVS Caremark has led the industry in evolving the pharmacy benefit management model and has delivered value to our customers and clients," said Ed DeVaney, Executive Vice President CVS Health and President, CVS Caremark. "Today's agreement advances and reinforces the changes we have already put in place and ensures affordability for families and patients across the country. CVS Caremark remains committed to lowering costs and bringing greater transparency to prescription drug pricing."
The changes CVS Caremark has made, and continues to make, are lowering the cost of health care for millions of people:
- Last year alone, CVS Caremark negotiated with pharmaceutical companies to save our clients and their members nearly
$80 billion - As an early advocate of offering point-of-sale rebates to our clients, CVS Caremark delivered nearly
$900 million - Through greater client adoption of point-of-sale rebates, and continued innovation, we expect to help our clients drive estimated savings of
$450 million
As outlined in the agreement CVS Caremark will implement a series of actions into its standard offering to commercial clients, including:
- Aligning certain member cost sharing more closely with the net cost of medications after rebates to help push more savings to members at the point-of-sale
- Simplifying pricing structures by moving away from rebate guarantees and spread pricing
- Expanding transparency through enhanced reporting on drug pricing, rebates, and member payments, along with disclosure of broker and consultant compensation
- Expanding affordability programs for medicines, including a new offering that will cap members' insulin costs at
$25 - Promoting point-of-sale rebate passthrough as a standard option to encourage plan sponsors to share drug cost savings more directly with members at the pharmacy counter
- Delinking manufacturer compensation from list prices
- Transitioning to acquisition-based reimbursement for independent retail pharmacies to ensure reimbursements are more closely aligned with their actual costs
- Counting TrumpRx purchases toward member deductibles and out-of-pocket maximums where allowed by law, subject to certain conditions in the settlement
CVS Caremark continues to introduce innovations that simplify the pharmacy experience and help lower prescription drug costs. These efforts include expanding automated prior authorization technology, accelerating the adoption of lower cost biosimilars through formulary strategies, and offering benefit designs that provide greater transparency and predictability in prescription pricing.
Many of the measures in the agreement align with CVS Caremark's existing affordability and transparency initiatives, including point-of-sale rebate options, flat-dollar copays, copay caps,
CVS Caremark will begin implementing the provisions of the agreement in accordance with timelines established with the FTC and will continue working with regulators, employers, and industry partners to strengthen transparency and affordability across the pharmacy benefit system.
About CVS Health
CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Media contact
Ethan Slavin
860-273-6095
Ethan.Slavin@CVSHealth.com
Investor contact
Larry McGrath
800-201-0938
InvestorInfo@CVSHealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-caremark-announces-agreement-with-ftc-to-further-advance-industry-leading-approaches-to-transparency-and-affordability-302825537.html
SOURCE CVS Health